Filter by Category: Clinical Trial Support

Evaluation of Delafloxacin Activity and Treatment Outcome for Phase 3 Acute Bacterial Skin and Skin Structure Clinical Trial Anaerobic Isolates.

Evaluation of Delafloxacin Activity and Treatment Outcome for Phase 3 Acute Bacterial Skin and Skin Structure Clinical Trial Anaerobic Isolates. Lead author: D Shortridge, presented at IDWeek 2018, October 3-7, San Francisco, CA, USA
#2373

Activity of Fosfomycin against Gram-Negative Baseline Bacterial Isolates from Patients in a Phase 3 Complicated Urinary Tract Infection Trial (ZEUS)

Activity of Fosfomycin against Gram-Negative Baseline Bacterial Isolates from Patients in a Phase 3 Complicated Urinary Tract Infection Trial (ZEUS). Lead author: D Shortridge, presented at ASM Microbe 2018, June 7-11, Atlanta, GA, USA
# Saturday-633

Current Assessment of Oritavancin Activity against Multidrug-Resistant Enterococcal Clinical Isolates

Current Assessment of Oritavancin Activity against Multidrug-Resistant Enterococcal Clinical Isolates. Lead author: RE Mendes, presented at ASM Microbe 2018, June 7-11, Atlanta, GA, USA
# Friday-452

Characterization of β-Lactam Resistance Mechanisms among Baseline Pseudomonas aeruginosa from 5 Ceftazidime-Avibactam Phase 3 Clinical Trials

Characterization of β-Lactam Resistance Mechanisms among Baseline Pseudomonas aeruginosa from 5 Ceftazidime-Avibactam Phase 3 Clinical Trials, Lead author: Mendes RE, presented at IDWeek 2017, October 4-8, San Diego, CA, USA
Poster #326

β-Lactamase characterization of Gram-negative pathogens recovered from patients enrolled in the phase 2 trials for ceftazidime-avibactam: clinical efficacies analyzed against subsets of molecularly characterized isolates.

β-Lactamase characterization of Gram-negative pathogens recovered from patients enrolled in the phase 2 trials for ceftazidime-avibactam: clinical efficacies analyzed against subsets of molecularly characterized isolates. by Mendes RE, Castanheira M, Gasink L, Stone GG, Nichols WW, Flamm RK and Jones RN published in Antimicrob. Agents. Chemother. 2016; 60 (3): 1328-1335

ß-lactamase characterization of baseline Enterobacteriaceae from Phase 3 trials of ceftazidime-avibactam for the treatment of complicated urinary tract infections

ß-lactamase characterization of baseline Enterobacteriaceae from Phase 3 trials of ceftazidime-avibactam for the treatment of complicated urinary tract infections, Lead author: Mendes RE, presented at 26th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 9-12, 2016, Amsterdam, Netherlands

Beta-lactamase characterization of Gram-negative pathogens recovered from patients enrolled in the phase 2 trials for ceftazidime-avibactam: Clinical efficacies analyzed against subsets of molecularly characterized isolates.

Beta-Lactamase characterization of Gram-negative pathogens recovered from patients enrolled in the phase 2 trials for ceftazidime-avibactam: Clinical efficacies analyzed against subsets of molecularly characterized isolates. by Mendes RE, Castanheira M, Gasink L, Stone GG, Nichols WW, Flamm RK and Jones RN. published in Antimicrob. Agents. Chemother. 2015; 60 (3): 1328-1335

ß-Lactamase Characterization Enterobacteriaceae Baseline Pathogens from Two Phase 3 Trials of CAZ-AVI

ß-Lactamase Characterization Enterobacteriaceae Baseline Pathogens from Two Phase 3 Trials of CAZ-AVI, Lead author: Mendes RE, presented at 55th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 17-21,2015, San Diego, CA

Genotypic characterization of methicillin-mesistant Staphylococcus aureus recovered at baseline from Phase 3 pneumonia clinical trials for ceftobiprole.

Genotypic characterization of methicillin-mesistant Staphylococcus aureus recovered at baseline from Phase 3 pneumonia clinical trials for ceftobiprole. by Mendes RE, Deshpande LM, Costello AJ, Farrell DJ, Jones RN and Flamm RK published in Microb. Drug Resist.: 2016; 22 (1): 53-58,

Potency and spectrum of activity of AN3365, a novel boron-containing protein synthesis inhibitor, tested against clinical isolates of Enterobacteriaceae and non-fermentative Gram-negative bacilli.

Potency and spectrum of activity of AN3365, a novel boron-containing protein synthesis inhibitor, tested against clinical isolates of Enterobacteriaceae and non-fermentative Gram-negative bacilli. by Mendes RE, Alley MR, Sader HS, Biedenbach DJ and Jones RN published in Antimicrob. Agents Chemother. 2013; 57 (6): 2849-2857